| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 100 | 2024 | 542 | 15.880 |
Why?
|
| Cyclophosphamide | 83 | 2023 | 422 | 14.820 |
Why?
|
| Bone Marrow Transplantation | 60 | 2023 | 577 | 9.720 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 55 | 2024 | 1198 | 8.520 |
Why?
|
| Transplantation Conditioning | 49 | 2023 | 323 | 7.340 |
Why?
|
| Immunosuppressive Agents | 36 | 2022 | 644 | 6.260 |
Why?
|
| Hematologic Neoplasms | 31 | 2023 | 286 | 5.760 |
Why?
|
| Leukemia, Myeloid, Acute | 21 | 2024 | 532 | 4.250 |
Why?
|
| Transplantation, Haploidentical | 15 | 2020 | 16 | 4.200 |
Why?
|
| Transplantation, Homologous | 50 | 2024 | 659 | 3.700 |
Why?
|
| HLA Antigens | 22 | 2020 | 243 | 3.070 |
Why?
|
| Tissue Donors | 21 | 2023 | 496 | 2.210 |
Why?
|
| Unrelated Donors | 15 | 2023 | 82 | 2.040 |
Why?
|
| Histocompatibility Testing | 21 | 2020 | 148 | 1.700 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2016 | 216 | 1.380 |
Why?
|
| Antilymphocyte Serum | 3 | 2019 | 56 | 1.300 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2024 | 394 | 1.290 |
Why?
|
| T-Lymphocytes | 18 | 2023 | 1677 | 1.280 |
Why?
|
| Stem Cell Transplantation | 7 | 2017 | 239 | 1.230 |
Why?
|
| Antineoplastic Agents, Alkylating | 8 | 2017 | 99 | 1.180 |
Why?
|
| Tacrolimus | 5 | 2021 | 99 | 1.150 |
Why?
|
| Myeloablative Agonists | 5 | 2021 | 25 | 1.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2023 | 805 | 1.130 |
Why?
|
| Haplotypes | 8 | 2016 | 519 | 1.060 |
Why?
|
| Histocompatibility | 13 | 2020 | 46 | 1.040 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2021 | 137 | 0.990 |
Why?
|
| Humans | 137 | 2024 | 123224 | 0.980 |
Why?
|
| B-Lymphocytes | 8 | 2022 | 518 | 0.970 |
Why?
|
| Allografts | 11 | 2018 | 190 | 0.970 |
Why?
|
| Major Histocompatibility Complex | 3 | 2017 | 51 | 0.970 |
Why?
|
| Lymphoma | 6 | 2021 | 321 | 0.950 |
Why?
|
| Recurrence | 21 | 2023 | 1423 | 0.940 |
Why?
|
| Middle Aged | 65 | 2023 | 26016 | 0.940 |
Why?
|
| Transplantation Chimera | 11 | 2016 | 39 | 0.880 |
Why?
|
| Immune Reconstitution | 2 | 2022 | 6 | 0.850 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 319 | 0.840 |
Why?
|
| Adult | 64 | 2023 | 29072 | 0.810 |
Why?
|
| Immune System Diseases | 1 | 2022 | 43 | 0.810 |
Why?
|
| Calcineurin Inhibitors | 1 | 2021 | 28 | 0.770 |
Why?
|
| Aged | 47 | 2021 | 19098 | 0.750 |
Why?
|
| Young Adult | 32 | 2023 | 8865 | 0.730 |
Why?
|
| Ursidae | 1 | 2020 | 2 | 0.730 |
Why?
|
| Immune Tolerance | 3 | 2023 | 145 | 0.720 |
Why?
|
| Disease-Free Survival | 16 | 2021 | 861 | 0.720 |
Why?
|
| Male | 70 | 2024 | 60118 | 0.720 |
Why?
|
| Chimerism | 2 | 2019 | 28 | 0.700 |
Why?
|
| Leukemia | 4 | 2021 | 375 | 0.680 |
Why?
|
| Chronic Disease | 17 | 2024 | 1168 | 0.680 |
Why?
|
| Bone Marrow | 9 | 2022 | 323 | 0.670 |
Why?
|
| Bronchiolitis Obliterans | 7 | 2022 | 39 | 0.670 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 258 | 0.670 |
Why?
|
| Methotrexate | 1 | 2021 | 341 | 0.670 |
Why?
|
| Lymphocyte Activation | 9 | 2019 | 677 | 0.660 |
Why?
|
| Aldehyde Dehydrogenase | 2 | 2022 | 40 | 0.650 |
Why?
|
| Female | 71 | 2024 | 65550 | 0.630 |
Why?
|
| Busulfan | 2 | 2015 | 44 | 0.620 |
Why?
|
| Biomarkers | 4 | 2018 | 2946 | 0.610 |
Why?
|
| Whole-Body Irradiation | 6 | 2019 | 65 | 0.590 |
Why?
|
| Cell Differentiation | 2 | 2024 | 1907 | 0.590 |
Why?
|
| Chemoprevention | 2 | 2016 | 59 | 0.590 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2018 | 47 | 0.580 |
Why?
|
| Germinal Center | 4 | 2022 | 38 | 0.570 |
Why?
|
| Graft Survival | 7 | 2016 | 525 | 0.570 |
Why?
|
| Immunomodulation | 3 | 2020 | 81 | 0.560 |
Why?
|
| Immunologic Factors | 3 | 2020 | 179 | 0.550 |
Why?
|
| Treatment Outcome | 31 | 2024 | 12141 | 0.550 |
Why?
|
| Cancer Vaccines | 3 | 2019 | 186 | 0.550 |
Why?
|
| Anemia, Aplastic | 4 | 2023 | 58 | 0.550 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2022 | 193 | 0.530 |
Why?
|
| Mice, Inbred BALB C | 12 | 2020 | 1002 | 0.530 |
Why?
|
| Survival Analysis | 12 | 2019 | 1472 | 0.520 |
Why?
|
| Vidarabine | 6 | 2014 | 79 | 0.510 |
Why?
|
| Animals | 38 | 2024 | 33759 | 0.500 |
Why?
|
| Mice | 31 | 2024 | 17503 | 0.500 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2020 | 30 | 0.490 |
Why?
|
| Transplantation Tolerance | 2 | 2016 | 15 | 0.490 |
Why?
|
| Graft vs Host Reaction | 4 | 2008 | 9 | 0.490 |
Why?
|
| Dendritic Cells | 2 | 2009 | 403 | 0.480 |
Why?
|
| Acute Disease | 9 | 2022 | 1093 | 0.480 |
Why?
|
| Drug Monitoring | 1 | 2015 | 157 | 0.470 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 85 | 0.460 |
Why?
|
| Lymphocyte Transfusion | 4 | 2013 | 57 | 0.440 |
Why?
|
| Lymphoma, B-Cell | 3 | 2015 | 137 | 0.430 |
Why?
|
| Immunotherapy | 6 | 2022 | 659 | 0.430 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2019 | 38 | 0.430 |
Why?
|
| Adolescent | 26 | 2023 | 19110 | 0.410 |
Why?
|
| Lung Transplantation | 1 | 2016 | 316 | 0.410 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 216 | 0.410 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 1661 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 795 | 0.380 |
Why?
|
| Haploidy | 3 | 2016 | 19 | 0.380 |
Why?
|
| Lymphocyte Depletion | 5 | 2016 | 124 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 1232 | 0.370 |
Why?
|
| Hypertension | 1 | 2019 | 1287 | 0.370 |
Why?
|
| Time Factors | 9 | 2021 | 6221 | 0.360 |
Why?
|
| Isoantibodies | 3 | 2018 | 70 | 0.340 |
Why?
|
| Mice, Inbred C57BL | 14 | 2020 | 4353 | 0.340 |
Why?
|
| Sirolimus | 2 | 2013 | 220 | 0.340 |
Why?
|
| Hodgkin Disease | 4 | 2020 | 293 | 0.330 |
Why?
|
| Immune System | 2 | 2009 | 87 | 0.330 |
Why?
|
| Lymphocytes | 3 | 2019 | 401 | 0.330 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2014 | 474 | 0.330 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 1088 | 0.320 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2022 | 15 | 0.310 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 117 | 0.310 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 212 | 0.310 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 262 | 0.310 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2008 | 19 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2007 | 162 | 0.300 |
Why?
|
| Immunophenotyping | 5 | 2022 | 330 | 0.300 |
Why?
|
| Remission Induction | 8 | 2020 | 300 | 0.290 |
Why?
|
| Retrospective Studies | 19 | 2023 | 16033 | 0.290 |
Why?
|
| Immunologic Memory | 3 | 2024 | 180 | 0.290 |
Why?
|
| Langerhans Cells | 1 | 2006 | 21 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2022 | 801 | 0.270 |
Why?
|
| Proteomics | 2 | 2022 | 479 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2016 | 1005 | 0.260 |
Why?
|
| Interleukin-10 | 1 | 2007 | 171 | 0.260 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 4273 | 0.250 |
Why?
|
| Cytarabine | 3 | 2021 | 98 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2023 | 6040 | 0.250 |
Why?
|
| Graft Rejection | 5 | 2018 | 582 | 0.240 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2013 | 39 | 0.240 |
Why?
|
| Multiple Myeloma | 2 | 2017 | 169 | 0.230 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 45 | 0.230 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 2019 | 77 | 0.230 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2024 | 41 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 490 | 0.210 |
Why?
|
| Cellular Senescence | 1 | 2024 | 161 | 0.210 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 368 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 1118 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 533 | 0.210 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2022 | 7 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 1239 | 0.200 |
Why?
|
| Neoplasm Grading | 3 | 2018 | 268 | 0.200 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2022 | 57 | 0.200 |
Why?
|
| Arginine | 1 | 2024 | 303 | 0.200 |
Why?
|
| Lymphocyte Subsets | 1 | 2022 | 38 | 0.200 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2015 | 96 | 0.190 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 268 | 0.190 |
Why?
|
| Germany | 1 | 2021 | 84 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2018 | 15 | 0.190 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 294 | 0.190 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 50 | 0.190 |
Why?
|
| Survival Rate | 6 | 2018 | 1996 | 0.190 |
Why?
|
| Child | 15 | 2023 | 24241 | 0.190 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 530 | 0.180 |
Why?
|
| Postoperative Care | 2 | 2016 | 295 | 0.180 |
Why?
|
| Cyclosporine | 2 | 2014 | 146 | 0.180 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 145 | 0.180 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2011 | 28 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 105 | 0.170 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 5049 | 0.170 |
Why?
|
| Leukemia, Experimental | 1 | 2020 | 15 | 0.170 |
Why?
|
| Blood Transfusion | 1 | 2002 | 301 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 5 | 2016 | 1009 | 0.170 |
Why?
|
| Thalidomide | 1 | 2020 | 36 | 0.170 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 52 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 73 | 0.170 |
Why?
|
| Donor Selection | 2 | 2019 | 52 | 0.170 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 5 | 0.170 |
Why?
|
| Machine Learning | 1 | 2022 | 219 | 0.160 |
Why?
|
| Transcriptome | 2 | 2022 | 905 | 0.160 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 16 | 0.160 |
Why?
|
| Postoperative Complications | 3 | 2020 | 3014 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 57 | 0.160 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 53 | 0.160 |
Why?
|
| Nephrocalcinosis | 1 | 2018 | 7 | 0.160 |
Why?
|
| Rituximab | 3 | 2015 | 155 | 0.160 |
Why?
|
| HIV-2 | 2 | 1995 | 8 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 74 | 0.160 |
Why?
|
| Hypercalcemia | 1 | 2018 | 39 | 0.160 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 9 | 0.160 |
Why?
|
| Gene Expression | 4 | 2018 | 1566 | 0.150 |
Why?
|
| Telomere Homeostasis | 1 | 2018 | 42 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 37 | 0.150 |
Why?
|
| Skin Transplantation | 2 | 2013 | 60 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1682 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 51 | 0.150 |
Why?
|
| Leukocyte Common Antigens | 2 | 2015 | 90 | 0.150 |
Why?
|
| Neoplasms | 4 | 2017 | 2758 | 0.150 |
Why?
|
| Ipilimumab | 1 | 2018 | 45 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1151 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 183 | 0.150 |
Why?
|
| Prognosis | 3 | 2022 | 4514 | 0.150 |
Why?
|
| Siblings | 2 | 2019 | 195 | 0.150 |
Why?
|
| Telomerase | 1 | 2018 | 161 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 69 | 0.150 |
Why?
|
| Consensus | 4 | 2023 | 612 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 118 | 0.140 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 110 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 2 | 2016 | 217 | 0.140 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2017 | 10 | 0.140 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 16 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 130 | 0.140 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 39 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 30 | 0.140 |
Why?
|
| Dogs | 1 | 2018 | 765 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2018 | 207 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 44 | 0.140 |
Why?
|
| Proteins | 1 | 2022 | 1038 | 0.130 |
Why?
|
| Gene Products, rev | 2 | 1996 | 11 | 0.130 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2018 | 201 | 0.130 |
Why?
|
| Salvage Therapy | 4 | 2012 | 193 | 0.130 |
Why?
|
| Child, Preschool | 12 | 2023 | 13888 | 0.130 |
Why?
|
| Antigens, Neoplasm | 3 | 2019 | 387 | 0.130 |
Why?
|
| Radioimmunotherapy | 1 | 2015 | 2 | 0.130 |
Why?
|
| Pyridones | 1 | 2017 | 112 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2012 | 730 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 3 | 2012 | 334 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 55 | 0.130 |
Why?
|
| Virus Replication | 3 | 1996 | 603 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2015 | 35 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2017 | 123 | 0.130 |
Why?
|
| Flow Cytometry | 4 | 2015 | 803 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 255 | 0.120 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 108 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 66 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 369 | 0.120 |
Why?
|
| Receptors, IgG | 1 | 2015 | 54 | 0.120 |
Why?
|
| Gene Products, tat | 1 | 1995 | 28 | 0.120 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 237 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2015 | 374 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 105 | 0.120 |
Why?
|
| Lymphoid Tissue | 1 | 2014 | 45 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 1995 | 101 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 455 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 211 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1682 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 121 | 0.110 |
Why?
|
| Incidence | 4 | 2017 | 3048 | 0.110 |
Why?
|
| Transplantation, Isogeneic | 3 | 2016 | 15 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2017 | 809 | 0.110 |
Why?
|
| HIV | 1 | 1995 | 179 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 667 | 0.110 |
Why?
|
| Mice, Knockout | 5 | 2020 | 3718 | 0.110 |
Why?
|
| Bayes Theorem | 1 | 2014 | 278 | 0.110 |
Why?
|
| Pyrroles | 1 | 1995 | 177 | 0.110 |
Why?
|
| Macrophages | 1 | 2017 | 605 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2012 | 21 | 0.100 |
Why?
|
| Histiocytic Sarcoma | 1 | 2012 | 4 | 0.100 |
Why?
|
| Monocytes | 1 | 1995 | 346 | 0.100 |
Why?
|
| Mice, Inbred DBA | 2 | 2002 | 48 | 0.100 |
Why?
|
| Mycophenolic Acid | 2 | 2012 | 51 | 0.100 |
Why?
|
| Models, Animal | 3 | 2016 | 464 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 554 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2014 | 304 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2018 | 988 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 667 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 523 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1781 | 0.100 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 1386 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 3274 | 0.100 |
Why?
|
| Desensitization, Immunologic | 1 | 2013 | 97 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 622 | 0.090 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 23 | 0.090 |
Why?
|
| Azacitidine | 1 | 2010 | 54 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2019 | 66 | 0.090 |
Why?
|
| Transplantation, Autologous | 2 | 2009 | 297 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1872 | 0.090 |
Why?
|
| United States | 2 | 2021 | 10637 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 90 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2020 | 753 | 0.080 |
Why?
|
| Risk Factors | 4 | 2017 | 10015 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2009 | 29 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 58 | 0.080 |
Why?
|
| Mutation | 2 | 2021 | 5773 | 0.080 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2008 | 7 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 369 | 0.080 |
Why?
|
| Filgrastim | 1 | 2008 | 15 | 0.080 |
Why?
|
| DNA Damage | 2 | 2024 | 505 | 0.080 |
Why?
|
| HIV Infections | 1 | 2020 | 1874 | 0.080 |
Why?
|
| Blood Component Transfusion | 1 | 2008 | 53 | 0.080 |
Why?
|
| Infant | 7 | 2020 | 12350 | 0.070 |
Why?
|
| Graft vs Tumor Effect | 1 | 2007 | 7 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 2016 | 229 | 0.070 |
Why?
|
| Secondary Prevention | 3 | 2016 | 212 | 0.070 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 381 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 437 | 0.070 |
Why?
|
| Cytokines | 3 | 2018 | 1285 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 652 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2006 | 35 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 311 | 0.070 |
Why?
|
| Transplants | 1 | 2006 | 36 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2022 | 572 | 0.070 |
Why?
|
| Etoposide | 2 | 2020 | 117 | 0.060 |
Why?
|
| Living Donors | 1 | 2006 | 112 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 115 | 0.060 |
Why?
|
| Disease Progression | 3 | 2016 | 2025 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2016 | 151 | 0.060 |
Why?
|
| Homeostasis | 1 | 2009 | 682 | 0.060 |
Why?
|
| Hematopoiesis | 2 | 2009 | 216 | 0.060 |
Why?
|
| Risk | 2 | 2017 | 747 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 376 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 375 | 0.060 |
Why?
|
| Pulmonary Fibrosis | 2 | 2017 | 96 | 0.050 |
Why?
|
| Methylation | 1 | 2024 | 226 | 0.050 |
Why?
|
| Skin | 1 | 2006 | 505 | 0.050 |
Why?
|
| Interferon Type I | 1 | 2024 | 107 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 29 | 0.050 |
Why?
|
| Age Factors | 2 | 2015 | 2802 | 0.050 |
Why?
|
| Transfection | 2 | 1995 | 1068 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 459 | 0.050 |
Why?
|
| Cell Separation | 2 | 2015 | 232 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 3316 | 0.050 |
Why?
|
| Medicine in the Arts | 1 | 2002 | 9 | 0.050 |
Why?
|
| Mice, Inbred AKR | 1 | 2001 | 14 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 118 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1306 | 0.050 |
Why?
|
| HIV-1 | 2 | 1996 | 465 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 806 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2002 | 137 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 177 | 0.050 |
Why?
|
| North America | 1 | 2002 | 239 | 0.050 |
Why?
|
| Cell Count | 1 | 2002 | 250 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3042 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2002 | 571 | 0.050 |
Why?
|
| Piperidines | 2 | 2014 | 198 | 0.050 |
Why?
|
| Patient Selection | 2 | 2015 | 685 | 0.050 |
Why?
|
| Europe | 1 | 2002 | 374 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1061 | 0.050 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2021 | 75 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2019 | 2813 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 132 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 62 | 0.040 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 92 | 0.040 |
Why?
|
| Alemtuzumab | 2 | 2012 | 88 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 312 | 0.040 |
Why?
|
| Forecasting | 1 | 2002 | 354 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2016 | 510 | 0.040 |
Why?
|
| Hexosamines | 1 | 2020 | 16 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 254 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 42 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 157 | 0.040 |
Why?
|
| Spleen | 2 | 2016 | 272 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2019 | 3 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 766 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 770 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 252 | 0.040 |
Why?
|
| Receptors, OX40 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 64 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 79 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1996 | 17 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 501 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1213 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 267 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 113 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 383 | 0.040 |
Why?
|
| Syndrome | 2 | 2014 | 1115 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 218 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 4489 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 714 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 209 | 0.030 |
Why?
|
| Models, Immunological | 1 | 2016 | 35 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 115 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 235 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2017 | 61 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2017 | 118 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2016 | 50 | 0.030 |
Why?
|
| RNA, Catalytic | 1 | 1996 | 15 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 11 | 0.030 |
Why?
|
| San Francisco | 1 | 2016 | 17 | 0.030 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2015 | 3 | 0.030 |
Why?
|
| Karyotyping | 1 | 2016 | 330 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 863 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 423 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 478 | 0.030 |
Why?
|
| Baltimore | 1 | 2015 | 13 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 188 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2015 | 12 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2015 | 121 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 1995 | 56 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 224 | 0.030 |
Why?
|
| Oxazines | 1 | 2015 | 25 | 0.030 |
Why?
|
| Defective Viruses | 1 | 1995 | 18 | 0.030 |
Why?
|
| Drug Antagonism | 1 | 1995 | 13 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 68 | 0.030 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 30 | 0.030 |
Why?
|
| Morpholines | 1 | 2015 | 56 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2016 | 229 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 53 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 326 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 429 | 0.030 |
Why?
|
| Receptors, Interleukin-21 | 1 | 2014 | 1 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2014 | 7 | 0.030 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2014 | 4 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1394 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1995 | 170 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 37 | 0.030 |
Why?
|
| CD40 Antigens | 1 | 2014 | 24 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 354 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 661 | 0.030 |
Why?
|
| Adenine | 1 | 2014 | 99 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 3091 | 0.030 |
Why?
|
| CD40 Ligand | 1 | 2014 | 64 | 0.030 |
Why?
|
| ABO Blood-Group System | 1 | 2014 | 65 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 354 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 340 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 514 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 353 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 224 | 0.030 |
Why?
|
| RNA, Viral | 1 | 1996 | 541 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1995 | 809 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 118 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3868 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1995 | 348 | 0.030 |
Why?
|
| Pentostatin | 1 | 2012 | 11 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 12 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2014 | 170 | 0.030 |
Why?
|
| Cell Line | 2 | 1996 | 2771 | 0.030 |
Why?
|
| Etanercept | 1 | 2012 | 38 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 63 | 0.030 |
Why?
|
| Wound Healing | 1 | 2016 | 452 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 348 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1168 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 239 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 285 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2830 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2013 | 141 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2011 | 1 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 2390 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2011 | 98 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 62 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1173 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1995 | 1584 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2010 | 27 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 27 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 421 | 0.020 |
Why?
|
| Cytosine | 1 | 2010 | 56 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2307 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 8108 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 178 | 0.020 |
Why?
|
| Flavonoids | 1 | 2010 | 78 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 202 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1401 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2009 | 256 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1260 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1309 | 0.020 |
Why?
|
| Fever | 1 | 2011 | 296 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 1476 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1292 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 349 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 459 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2586 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2839 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1414 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 823 | 0.010 |
Why?
|
| Hospitalization | 1 | 2011 | 1726 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2002 | 50 | 0.010 |
Why?
|
| Reticulocyte Count | 1 | 2001 | 2 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 1 | 2001 | 21 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 247 | 0.010 |
Why?
|
| Linear Models | 1 | 2001 | 669 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 7161 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 892 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1996 | 478 | 0.010 |
Why?
|
| Liver | 1 | 2001 | 1734 | 0.010 |
Why?
|